Okay, let's tackle this question. The user wants me to explain which anticancer drug acts by hypomethylation. First, I need to remember the mechanisms of action of various anticancer drugs. Hypomethylation is related to DNA methylation, which is an epigenetic modification. Drugs that cause hypomethylation would inhibit DNA methyltransferases, leading to reactivation of silenced genes.

So, the correct answer is probably a demethylating agent. The two main drugs I recall that work this way are 5-azacytidine and decitabine. These are used in myelodysplastic syndromes. They get incorporated into DNA and inhibit DNA methyltransferases, causing hypomethylation.

Now, looking at the options, if the correct answer is one of these two, the other options are likely to be drugs with different mechanisms. Let's think about the other options. For example, if an option is a topoisomerase inhibitor like etoposide, that's a different mechanism. Or maybe an alkylating agent like cyclophosphamide, which works by crosslinking DNA. Another option might be a histone deacetylase inhibitor, like vorinostat, which causes hyperacetylation rather than hypomethylation.

So, the key here is distinguishing between different epigenetic drugs. Demethylating agents cause hypomethylation, while HDAC inhibitors cause hyperacetylation. The question is testing the understanding of these distinct mechanisms. The clinical pearl would be to remember that 5-azacytidine and decitabine are the primary hypomethylating agents used in MDS and certain leukemias. Students often confuse these with other epigenetic drugs, so it's important to note the specific mechanisms and their applications.

**Core Concept**
Hypomethylation of DNA is an epigenetic mechanism used by certain anticancer drugs to reactivate tumor suppressor genes silenced by hypermethylation. These drugs inhibit DNA methyltransferases (DNMTs), leading to global DNA demethylation.

**Why the Correct Answer is Right**
5-azacytidine (or decitabine) is a nucleoside analog that incorporates into DNA during replication. It covalently binds to and inhibits DNMT1, preventing methylation of cytosine residues. This reactivates silenced tumor suppressor genes, restoring their anti-cancer functions. These agents are FDA-approved for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with specific mutations.

**Why Each Wrong Option is Incorrect**
**Option A:** *Etoposide* is a topoisomerase II inhibitor causing DNA strand breaks, not methylation changes.
**Option B:** *Cyclophosphamide* is an alkylating agent that crosslinks DNA, not an epigenetic modifier.
**Option C:** *Vorinostat* is a histone deacetylase (HDAC) inhibitor causing hyperacetylation, not hypomethylation.

**Clinical Pearl / High-Yield Fact**
Remember: **"Az" in 5-azacytidine hints at "azide" structure, a key feature of hypomethylating agents.** They are distinct from HDAC inhibitors (e.g

✓ Correct Answer: C. Decitabine